News
ANVS
1.790
0.00%
0.000
Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)
TipRanks · 2d ago
Annovis Bio’s New Long-Term Safety Study Puts Buntanetap Back in the Alzheimer’s Spotlight
TipRanks · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amylyx Pharmaceuticals Inc (AMLX), Annovis Bio (ANVS) and BioMarin Pharmaceutical (BMRN)
TipRanks · 3d ago
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity
Dow Jones · 3d ago
Annovis Bio Is Maintained at Buy by Canaccord Genuity
Dow Jones · 3d ago
Weekly Report: what happened at ANVS last week (0810-0814)?
Weekly Report · 4d ago
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Benzinga · 08/14 12:10
Annovis Bio GAAP EPS of -$0.40 beats by $0.05
Seeking Alpha · 08/14 12:05
*Annovis Bio 2Q Loss $14.8M >ANVS
Dow Jones · 08/14 12:05
*Annovis Bio 2Q Loss/Shr 40c >ANVS
Dow Jones · 08/14 12:05
Press Release: Annovis Provides Corporate Updates -2-
Dow Jones · 08/14 12:01
Press Release: Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Dow Jones · 08/14 12:01
Weekly Report: what happened at ANVS last week (0803-0807)?
Weekly Report · 08/10 09:03
Weekly Report: what happened at ANVS last week (0727-0731)?
Weekly Report · 08/03 09:03
Weekly Report: what happened at ANVS last week (0720-0724)?
Weekly Report · 07/27 09:03
Weekly Report: what happened at ANVS last week (0713-0717)?
Weekly Report · 07/20 09:03
Weekly Report: what happened at ANVS last week (0706-0710)?
Weekly Report · 07/13 09:03
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial
TipRanks · 07/10 10:31
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS)
TipRanks · 07/08 19:20
Annovis Bio Initiated at Buy by Roth Capital
Dow Jones · 07/08 09:18
More
Webull provides a variety of real-time ANVS stock news. You can receive the latest news about Annovis Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.